A Pyrazole Derivative Potently Inhibits Lymphocyte Ca$^{2+}$ Influx and Cytokine Production by Facilitating Transient Receptor Potential Melastatin 4 Channel Activity


Laboratory of Cell and Molecular Signaling, Center for Biomedical Research at the Queen’s Medical Center and John A. Burns School of Medicine at the University of Hawaii, Honolulu, Hawaii (H.C., A.B., A.F., R.P.); Inflammation Research, Pharmacology Laboratories (R.T., J.I., T.Y.), Medical Chemistry Research II, Chemistry Laboratories (H.K.), Institute for Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan; and Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts (P.L., J.-P.K.)

Received November 24, 2005; accepted January 10, 2006

ABSTRACT

3,5-Bis(trifluoromethyl)pyrazole derivative (BTP2) or N-[4–3, 5-bis(trifluoromethyl)pyrazol-1-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide (YM-58483) is an immunosuppressive compound that potently inhibits both Ca$^{2+}$ influx and interleukin-2 (IL-2) production in lymphocytes. We report here that BTP2 dose-dependently enhances transient receptor potential melastatin 4 (TRPM4), a Ca$^{2+}$-activated nonselective (CAN) cation channel that decreases Ca$^{2+}$ influx by depolarizing lymphocytes. The effect of BTP2 on TRPM4 occurs at low nanomolar concentrations and is highly specific, because other ion channels in T lymphocytes are not significantly affected, and the major Ca$^{2+}$ influx pathway in lymphocytes, $I_{\text{CRAC}}$, is blocked only at 100-fold higher concentrations. The efficacy of BTP2 in blocking IL-2 production is reduced approximately 100-fold when preventing TRPM4-mediated membrane depolarization, suggesting that the BTP2-mediated facilitation of TRPM4 channels represents the major mechanism for its immunosuppressive effect. Our results demonstrate that TRPM4 channels represent a previously unrecognized key element in lymphocyte Ca$^{2+}$signaling and that their facilitation by BTP2 supports cell membrane depolarization, which reduces the driving force for Ca$^{2+}$ entry and ultimately causes the potent suppression of cytokine release.

In many cells, receptor activation evokes an increase in cytosolic Ca$^{2+}$ concentration ([Ca$^{2+}$]$_i$) composed of release from intracellular stores followed by store-operated Ca$^{2+}$ entry via calcium release-activated calcium (CRAC) channels (Penner et al., 1993; Parekh and Penner, 1997; Putney et al., 2001). These channels are functionally best characterized in mast cells (Hoth and Penner, 1992, 1993) and T lymphocytes (Zweifach and Lewis, 1993; Premack et al., 1994) and are considered key elements for the activation of immune cells. The study of CRAC has been hampered by the lack of potent and specific pharmacological tools. At present, the most widely used organic blockers of store-operated calcium entry pathways are imidazole antimycotics, such as econazole, the closely related compound SKF-96365, and 2-aminothiazolidinophenyl borate (Mason et al., 1993; Chung et al., 1994; Franzius et al., 1994; Christian et al., 1996; Hermosura et al., 2002). However, none of these compounds is very potent or selective.

A class of pyrazole derivatives, bis(trifluoromethyl)pyrazoles (BTPs), has been reported to act as potent immuno-
suppressive compounds by inhibiting cytokine release (IL-2, IL-4, IL-5, interferon-γ, and others) from human lymphocytes and suppressing T-cell proliferation (Djuric et al., 2000; Trevilyan et al., 2001; Chen et al., 2002; Ishikawa et al., 2003). In addition, these compounds have proven effective in various immune disease-relevant rodent and nonhuman primate models, in which they inhibit trinitrochlorobenzene-induced contact hypersensitivity in mice (a model of T lymphocyte-mediated delayed type hypersensitivity) and Ascaris suum-induced immediate bronchoconstriction of cymolomus monkeys (an asthma model) (Djuric et al., 2000; Ishikawa et al., 2003). Despite the rather detailed characterization of the compound’s potent effects in many immune-based cellular and animal models, the mechanism by which BTPs inhibit cytokine production in lymphocytes remains unknown. The effects of BTPs are presumably linked to intracellular Ca$^{2+}$ signaling, because the pyrazole derivative BTP2 (Fig. 2D) potently inhibits thapsigargin-evoked Ca$^{2+}$ influx in the low nanomolar range (Ishikawa et al., 2003), and two recent reports suggest that BTP2 may inhibit the store-operated Ca$^{2+}$ current $I_{\text{CRAC}}$ (Zitt et al., 2004; He et al., 2005) and TRPC3 and TRPC5 channels (He et al., 2005).

The transient receptor potential (TRP) proteins represent an important family of mammalian ion channels that are believed to be involved in Ca$^{2+}$ signaling. Based on sequence similarities, the mammalian TRP channel family is divided into three subfamilies: TRPC, TRPV, and TRPM (Harteneck et al., 2000; Clapham et al., 2001; Montell et al., 2002a,b). TRPM4, specifically the longer splice variant TRPM4b (which we will refer to as TRPM4 throughout this manuscript), is a widely expressed Ca$^{2+}$-activated nonselective cation channel of the TRPM ion channel subfamily that does not conduct Ca$^{2+}$ but instead mediates cell membrane depolarization (Launay et al., 2002). In electrically nonexcitable cells, a depolarization would tend to decrease the driving force for Ca$^{2+}$ influx through store-operated Ca$^{2+}$ channels. Many other ion channels, such as voltage-dependent potassium (Kv1.3) channels (Lin et al., 1993; Hanson et al., 1999), intermediate/small-conductance calcium-activated potassium (IK/SK2) channels (Lin et al., 1993; Jensen et al., 1999; Desai et al., 2000; Wulff et al., 2000), and swelling-activated chloride (Cl$_{i\text{vol}}$) channels (Lewis et al., 1993; Ross et al., 1994), are also known to be involved in the regulation of the driving force for Ca$^{2+}$ influx, but they do so by hyperpolarizing the membrane potential (Penner et al., 1988; Cahalan and Chandy, 1997; Cahalan et al., 2001). Thus, the net Ca$^{2+}$ influx into a cell is not only determined by Ca$^{2+}$ entry pathways themselves, but also by ion channels that modulate the membrane potential.

In the present study, we investigated the mechanism by which BTP2 inhibits Ca$^{2+}$ signaling in Jurkat T cells. We demonstrate that BTP2 potently and selectively facilitates the activity of TRPM4, resulting in reduced Ca$^{2+}$ entry and cytokine release. This compound therefore represents a novel and promising pharmacological tool to inhibit Ca$^{2+}$ signaling in lymphocytes and other cell types that regulate Ca$^{2+}$ influx by the concerted actions of store-operated Ca$^{2+}$ channels and Ca$^{2+}$-activated cation channels.

**Materials and Methods**

**Cells.** HEK-293 cells transfected with the FLAG-human TRPM4b/pCDNA4/TO construct were grown on glass coverslips with Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, blasticidin (5 μg/ml), and zeocin (0.4 mg/ml). TRPM4b expression was induced 1 day before use by adding 1 μg/ml tetracycline to the culture medium, and patch-clamp experiments were performed 16 to 24 h after induction (for details, see Launay et al., 2002). Human leukemic T cells (Jurkat cells) were grown in RPMI 1640 medium (10% FBS) and rat basophilic leukemia cells (RBL-2H3 cells) in Dulbecco’s modified Eagle’s medium (10% FBS).

**Materials.** BTP2 (or YM-58483) and SKF-96365 were synthesized by Astellas Pharma Inc. (Tokyo, Japan). Econazole, margatoxin, apamin, charybdotoxin, and stilbenesulfonate 4,4-diisothiocyanostilbene-2,2′-disulfonic acid were purchased from Sigma and dissolved in dimethyl sulfoxide. Phytohemagglutinin (PHA) was obtained from Sigma (St. Louis, MO) and dissolved in phosphate-buffered saline.

**Solutions.** For $I_{\text{CRAC}}$ measurements, the standard bath solution had the following composition: 140 mM NaCl, 2.8 mM KCl, 10 mM CaCl$_2$, 2 mM MgCl$_2$, 10 mM CsCl, 10 mM glucose, and 10 mM HEPES-NaOH, pH 7.2, with osmolarity adjusted to approximately 320 mosM. Intracellular pipette-filling solutions contained 140 mM cesium glutamate, 8 mM NaCl, 1 mM MgCl$_2$, 10 mM cesium-β-APTA, and 10 mM HEPES-CsOH, pH 7.2, adjusted with CsOH. In experiments in which Ca$^{2+}$ was buffered to elevated levels, CaCl$_2$ was added as necessary [calculated with WebMaxC (http://www.stanford.edu/~cotton/webmaxc5.html), temperature = 24°C, pH = 7.2, ionic equivalent = 0.16]. Solution changes were performed by pressure ejection from a wide-tipped pipette.

**Electrophysiology.** Patch-clamp experiments were performed in the tight-seal whole-cell configuration at 21 to 25°C. High-resolution current recordings were acquired by a computer-based patch-clamp amplifier system (EPC-9; HEKA, Lambrecht, Germany). Patch pipettes had resistances between 2 and 4 MΩ after filling with the standard intracellular solution. Immediately after establishment of the whole-cell configuration, voltage ramps of 50- to 200-ms duration spanning the voltage range of −100 to +100 mV were delivered at a rate of 0.5 Hz over a period of 300 to 400 s. All voltages were corrected for a liquid junction potential of 10 mV between external and internal solutions when using glutamate as an intracellular anion. Currents were filtered at 2.9 kHz and were digitized at 100-μs intervals. Capacitive currents and series resistance were determined and corrected before each voltage ramp using the automatic capacitance compensation of the EPC-9. The low-resolution temporal development of membrane currents was assessed by extracellular current amplitude at −80 or +80 mV from individual ramp current records. Where applicable, statistical errors of averaged data are given as means ± S.E.M. with n determinations.

Voltage-dependent potassium (Kv1.3) currents were measured in Jurkat cells. The bath solution contained 160 mM NaCl, 4.5 mM KCl, 2 mM CaCl$_2$, 1 mM MgCl$_2$, and 10 mM HEPES-NaOH, pH 7.2. The internal solution contained 140 mM potassium glutamate, 2 mM MgCl$_2$, 1 mM CaCl$_2$, 10 mM potassium-β-APTA, and 10 mM HEPES-KOH, pH 7.2. Ramps were given every 30 s (−100 to +100 mV in 200 ms), and cells were held at −80 mV between ramps. Currents were not leak-subtracted.

Calcium-activated potassium (SK2) currents were measured in Jurkat cells. The bath solution contained 164.5 mM KCl, 2 mM CaCl$_2$, 1 mM MgCl$_2$, and 5 mM HEPES-KOH, pH 7.2. The internal solution contained 135 mM potassium aspartate, 2 mM MgCl$_2$, 1.1 mM potassium EGTA, and 10 mM HEPES-KOH, pH 7.2. Ramps were given every 2 s (−100 to +40 mV in 200 ms), and cells were held at −80 mV between ramps. Free intracellular [Ca$^{2+}$]$_i$ was adjusted to 1 μM.

Swelling-activated chloride (Cl$_{i\text{vol}}$) currents were measured in Jurkat cells. The bath solution contained 160 mM NaCl, 4.5 mM KCl, 1...
mM MgCl₂, 2 mM CaCl₂, and 5 mM HEPES-NaOH, pH 7.2. The internal solution contained 160 mM cesium glutamate, 2 mM MgCl₂, 0.1 mM CaCl₂, 1.1 mM cesium-EGTA, 4 mM sodium ATP, 100 mM glucose, and 10 mM HEPES-CsOH, pH 7.2. Ramps were given every 2 s (-100 to +100 mV in 200 ms), and cells were held at -60 mV between ramps.

TRPM4 currents were measured in Jurkat and HEK-293 cells overexpressing TRPM4b. The bath solution contained 140 mM NaCl, 2.8 mM KCl, 2 mM MgCl₂, 1 mM CaCl₂, 10 mM glucose, and 10 mM HEPES-NaOH, pH 7.2. The internal solution contained 120 mM potassium glutamate, 8 mM NaCl, 1 mM MgCl₂, 10 mM potassium-BAPTA, and 10 mM HEPES-KOH, pH 7.2. Ramps were given every 2 s (-100 to +100 mV in 50 ms), and cells were held at -80 mV between ramps. Free intracellular [Ca²⁺], was adjusted as indicated in the figure legends.

**IL-2 Production Assay.** Jurkat cells (5 x 10⁶ cells/ml) were placed in a 96-well microplate and incubated with either 10 μg/ml or 2 μg/ml PHA (Sigma) for 24 h, and the supernatant was collected from these cells after centrifugation (200g, 24°C for 3 min.). The concentration of IL-2 was measured by the human IL-2 ELISA system (human IL-2 ELISA Kit DuoSet; Genzyme Co., Cambridge, MA). Optical density values at 450 nm were measured with the use of a microplate reader (Spectra Max 190; Molecular Devices, Sunnyvale, CA). Data for BTP2-treated cells were normalized to those of untreated control cells.

**Calcium Measurements.** For Ca²⁺ measurements, Pura-2 acetoxymethyl ester-loaded cells (5 μM/30 min at 37°C) were kept in standard extracellular saline containing 140 mM NaCl, 2.8 mM KCl, 1 mM CaCl₂, 2 mM MgCl₂, 10 mM glucose, and 10 mM HEPES-NaOH, pH 7.2, and excited by wavelengths of 340 and 380 nm. Fluorescence emission of several cells was simultaneously recorded at a frequency of 1 Hz using a dual excitation fluorometric imaging system (TILL-Photons, Gräfelfingen, Germany) controlled by TILL-Vision software. Signals were computed into relative ratio units of the fluorescence intensity of the different wavelengths (340/380 nm).

**Results**

**Effect of BTP2 on I_CRAC.** Because BTP2 inhibits thapsigargin-induced Ca²⁺ influx (Ishikawa et al., 2003) and reportedly inhibits the store-operated calcium current I_CRAC (Zitt et al., 2004), we analyzed the effects of BTP2 on I_CRAC in RBL-2H3 and Jurkat T cells. I_CRAC was activated by a standard protocol after whole-cell break-in with 20 μM InsP₃ in the pipette solution. The time course of whole-cell current was monitored by 200-ms voltage ramps that spanned -100 to +100 mV and were applied every 2 s. Each voltage ramp yields a full current-voltage (I-V) relationship (Fig. 1C), and the I_CRAC time course is shown in Fig. 1A. It was constructed by measuring the whole-cell current amplitude on the ramp trace corresponding to ~80 mV, normalizing the current amplitude to the value obtained just before the application of compound, and plotting it as a function of time. Extracellularly applied BTP2 blocked InsP₃-evoked I_CRAC in Jurkat cells in a concentration-dependent manner (Fig. 1A). Complete inhibition of the current was obtained within 200 s after the addition of 10 μM BTP2. Lower concentrations also blocked, but they did so more slowly. Figure 1E shows the dose-response relationship for BTP2-mediated block of I_CRAC 300 s after application, along with the dose-response curve obtained for the reference compound econazole under identical experimental conditions (raw data not shown). In Jurkat cells, the apparent IC₅₀ values for BTP2 and econazole were 2.2 and 4.0 μM, respectively (Hill coefficient = 1.7 each).

**Fig. 1.** Effects of BTP2 on I_CRAC. Whole-cell currents were recorded in Jurkat cells and RBL-2H3 cells. I_CRAC was activated using intracellular solutions containing 20 μM InsP₃ and 10 mM BAPTA and was monitored by applying voltage ramps of 50-ms duration that ranged from -100 to +100 mV from a holding potential of 0 mV. Data are ± S.E.M. where applicable. A, average I_CRAC at ~80 mV (n = 3–10) in Jurkat cells. BTP2 (1, 1 μM; □, 3 μM; ○, 10 μM) was applied extracellularly as indicated by the bar. Currents were normalized to the amplitude at 150 s. B, average I_CRAC at ~80 mV (n = 3–10) in RBL-2H3 cells. BTP2 (1, 10 nM; □, 1 μM; ○, 10 μM) was applied extracellularly as indicated by the bar. Currents were normalized to the amplitude at 180 s. C, representative I-V relationships for fully activated I_CRAC at 180 s and fully inhibited I_CRAC (by 10 μM BTP2) at 480 s in Jurkat cells. D, Jurkat and RBL cells were perfused with standard internal solution containing 10 μM BTP2 (n = 10), which failed to block I_CRAC. At 180 s into the experiment, 10 μM BTP2 was applied extracellularly and caused complete block of I_CRAC. E, dose-response relationship for BTP2- and econazole-mediated block of I_CRAC in Jurkat cells (IC₅₀ value for BTP2 = 2.2 μM and for econazole = 4.0 μM, with Hill coefficients of 1.7 each). F, dose-response relationship for BTP2- and econazole-mediated block of I_CRAC in RBL-2H3 cells (IC₅₀ value for BTP2 = 0.5 μM and for econazole = 4.2 μM, with Hill coefficients of 1.4 each). G, average Ca²⁺ signals in intact Jurkat T cells stimulated with PHA (20 μg/ml). Control cells (□, n = 32) produced sustained changes in [Ca²⁺], whereas Ca²⁺ signals in cells that were exposed to 100 nM BTP2 (●, n = 58) returned to baseline within ~10 min. H, dose-response relationships for BTP2-induced inhibition of IL-2 production over different stimulation times. Jurkat cells (5 x 10⁶ cells/ml) were incubated with PHA (10 μg/ml) and various concentrations of BTP2. At the indicated times (range, 2–24 h), IL-2 content in the supernatant was measured by ELISA and normalized to control cells not treated with BTP2 (the absolute amounts of IL-2 in the absence of BTP2 were: 2 h = 9 ± 1.9 pg/ml; 4 h = 135 ± 54 pg/ml; 8 h = 702 ± 157 pg/ml; and 24 h = 1500 ± 329 pg/ml; mean ± S.E.M.).
Next, we studied the effect of BTP2 on $I_{\text{CRAC}}$ in RBL-2H3 cells and observed that BTP2 also blocks InsP$_3$-evoked $I_{\text{CRAC}}$ in these cells in a concentration-dependent manner (Fig. 1B). With an IC$_{50}$ value of 0.5 μM (Fig. 1F; Hill coefficient = 1.4), BTP2 seems slightly more potent in RBL cells than in Jurkat cells, whereas the potency of econazole in RBL cells (IC$_{50}$ = 4.2 μM; Hill coefficient = 1.4) was similar to that observed in Jurkat cells. To study the site of action, we included BTP2 in the pipette solution. Intracellularly applied BTP2 (10 μM) did not exhibit any inhibitory effect on $I_{\text{CRAC}}$ in either RBL-2H3 cells or Jurkat cells, and it did not affect the block of $I_{\text{CRAC}}$ induced by extracellularly applied BTP2 in either cell type (Fig. 1D). This suggests that the inhibitory action of BTP2 on $I_{\text{CRAC}}$ may be located extracellularly; however, we cannot completely rule out the possibility that the lipidphilicity of the compound might allow it to escape rapidly across the plasma membrane before affecting the channel.

Although the above results demonstrate that BTP2 can inhibit $I_{\text{CRAC}}$ in both RBL and Jurkat cells, the potency seems to be too low to account for the compound's ability to suppress cytokine production, which occurs in the low nanomolar range. Zitt et al. (2004) reported recently that $I_{\text{CRAC}}$ is inhibited by BTP2 at lower concentrations, but this effect requires hours to develop, and they arrived at an IC$_{50}$ value of approximately 10 nM after 24 h of preincubation with the compound (Zitt et al., 2004). He et al. (2005) reported that store-operated Ca$^{2+}$ entry was reduced much quicker, within approximately 10 min, but the concentrations required to do so in HEK-293 cells and DT40 B cells were found to be at least 1 order of magnitude higher (He et al., 2005), similar to the efficacy of BTP2 in blocking $I_{\text{CRAC}}$ in RBL cells (Fig. 1F).

To further assess the involvement of BTP2 in blocking $I_{\text{CRAC}}$ in Jurkat cells, we analyzed the kinetics of BTP2 action on both Ca$^{2+}$ signaling and cytokine production. Figure 1G illustrates the effect of 100 nM BTP2 on Jurkat Ca$^{2+}$ signals evoked by 10 μg/ml PHA. This relatively low concentration of BTP2 suppressed the PHA-induced Ca$^{2+}$ signals almost completely within approximately 10 min and therefore cannot be reconciled easily with the reported slow $I_{\text{CRAC}}$ inhibition (time constant = 98 min) (Zitt et al., 2004). We next analyzed the temporal development of the efficacy of BTP2 to suppress IL-2 release over variable time spans ranging from 2 to 24 h. Jurkat cells were stimulated with 10 μg/ml PHA, and IL-2 production was measured by ELISA at various times after the coapplication of PHA and various concentrations of BTP2. Figure 1H illustrates that there was no significant change in the potency with which BTP2 suppressed IL-2 release, because the IC$_{50}$ value remained constant in the low nanomolar range even when measuring IL-2 release as early as 2 h after stimulation, again suggesting that the main mechanism of action of BTP2 is engaged quickly and does not require several hours to develop. This would suggest that the $I_{\text{CRAC}}$ inhibition observed by Zitt et al. (2004) at low nanomolar concentrations may be caused by another event rather than as a direct effect on CRAC channels. Because BTP2 has been demonstrated to suppress lymphocyte proliferation (Trevillyan et al., 2001; Zitt et al., 2004), one possible reason for the decrease in $I_{\text{CRAC}}$ amplitude after long BTP2 preincubations could be that lymphocytes become arrested at a certain cell-cycle stage in which $I_{\text{CRAC}}$ is suppressed. Indeed, serum-starved RBL cells become arrested in G$_0$/G$_1$ and have been reported to lack significant $I_{\text{CRAC}}$ (Bodding, 2001). He et al. (2005) found a relatively fast inhibition of store-operated Ca$^{2+}$ influx, but the concentrations required probably reflect the inhibition of $I_{\text{CRAC}}$ we observe in, for example, RBL cells. Given that the effect of BTP2 even at low concentrations is relatively quick compared with the time course over which it compromises $I_{\text{CRAC}}$, we considered alternative or additional mechanisms that BTP2 may be targeting.

**Effect of BTP2 on Other Ionic Currents in Jurkat Cells.** Whole-cell recordings permit the direct measurement of several types of channel activity that may affect Ca$^{2+}$-signaling in Jurkat cells such as the voltage-dependent potassium channel Kv1.3, the small-conductance Ca$^{2+}$-activated potassium channel SK2, and volume regulatory Cl$^{-}$ channel Cl$_{vof}$. We first analyzed the efficacy of known inhibitors of these channels on PHA-stimulated cytokine production in Jurkat T lymphocytes. Of the presumed $I_{\text{CRAC}}$ inhibitors, BTP2, econazole, and SKF-96365 (10 μM each), only BTP2 completely inhibited PHA-induced IL-2 production (Fig. 2A), consistent with its complete inhibition of $I_{\text{CRAC}}$ at that concentration. Econazole also suppressed cytokine pro-

---

**Fig. 2.** Effects of channel blockers on IL-2 production and membrane currents in Jurkat cells. Jurkat cells (5 × 10$^6$ cells/ml) were incubated with PHA (2 μg/ml). Twenty-four hours after stimulation, IL-2 content in the supernatant was measured by ELISA. Data are x ± S.E.M. where applicable. A, effects of different individual channel blockers on IL-2 production ($n = 3$ each). BTP2 (10 μM) is indicated in gray, and the other compounds are shown as □. B, additive effects of different channel blockers (at the same concentration as in A) on IL-2 production in cells that were treated with 10 nM BTP2 plus the channel blockers (□) compared with 10 nM BTP2 inhibition alone (□). 10 nM BTP2 caused ~40% inhibition; $n = 3$ each. For comparison purposes, the broken line indicates the level of inhibition by 10 nM BTP2 alone. C, effects of BTP2 (□) and reference compounds (□) on different ion channels in Jurkat T cells ($n = 5–8$). D, chemical structure of BTP2.
duction, albeit not completely, whereas SKF-96365 was not very effective. The other inhibitors exhibited varying degrees of inhibition. The K⁺ channel blockers, including the Kv1.3-specific inhibitor margatoxin (1 nM), the SK2 inhibitor apamin (10 nM), and the IK inhibitor charybdotoxin (100 nM), produced inhibitory effects in the range of 30 to 50%, whereas the Clᵥ channel inhibitor stilbenedisulfonate 4,4'-disothiocyanato stilbene-2,2'-disulfonic acid (100 µM) was ineffective. The efficacy of K⁺ channel blockers to affect IL-2 production is consistent with the fact that they inhibit ion currents which promote Ca²⁺ influx via a membrane hyperpolarization. However, none of the compounds was able to suppress cytokine production completely. Moreover, none of the compounds was able to inhibit cytokine production completely. Moreover, none of the compounds was able to inhibit cytokine production completely.

To assess the specificity of BTP2, we tested for its effects on the K⁺ and Cl⁻ channels expressed in Jurkat cells. BTP2 did not significantly affect the activity of any of these channels, even at the highest concentration (10 µM) tested (Fig. 2C), with the possible exception of Cl⁻ currents, which were inhibited by ~50%. In addition, BTP2 showed no inhibitory effect on ADP-ribose-activated TRPM2 channels expressed in HEK-293 cells (Perraud et al., 2001; Sano et al., 2001) and inward rectifier K⁺ currents in RBL cells (Lindau and Fernandez, 1986). Given the significant discrepancy in the potency of BTP2 to inhibit IL-2 production at low nanomolar concentrations versus IC₅₀ inhibition with an IC₅₀ value of 2.1 µM and the lack of effect on K⁺ channels, we considered TRPM4, a CAN channel expressed in Jurkat cells (Launay et al., 2002, 2004), to be a possible target.

**Voltage and [Ca²⁺], Dependence of TRPM4.** We have shown previously that TRPM4 can be detected at RNA and protein levels in various T cells of murine and human origin and that these channels are functional in Jurkat T cells (Launay et al., 2004). Moreover, we have observed calcium-activated TRPM4-like currents in human primary T cells (A. Beck and R. Penner, unpublished observations). To assess TRPM4 function, we used Jurkat T cells as a model system and carried out experiments very similar to those described in Fig. 1A, except that the free Ca²⁺ concentration of the intracellular pipette solution was buffered to levels of 0.3 to 1.8 µM. Under these conditions, Jurkat cells indeed produce large cation currents with current-voltage signatures indistinguishable from those of TRPM4, and we refer to these currents as I_CAN. In initial experiments, application of BTP2 to maximally activated I_CAN did not yield any significant modification of the currents, either inhibitory or facilitatory (data not shown). However, these experiments were carried out at a holding potential of 0 mV, which yields maximal activation of I_CAN in Jurkat cells (Fig. 4A), whereas the resting potential of these cells is considerably more negative. The resting membrane potential is an important factor in determining TRPM4 behavior, because the channel exhibits a striking voltage dependence (Launay et al., 2002; Hofmann et al., 2003; Nilius et al., 2003). To assess the influence of membrane voltage on TRPM4 activity, we studied the voltage dependence of TRPM4 in HEK-293 cells.

Figure 3A illustrates the activation of Ca²⁺-activated currents in TRPM4 overexpressing HEK-293 cells kept at various membrane holding potentials and perfused with a solution in which [Ca²⁺], was buffered to 1.3 µM. Exemplary current-voltage relationships of TRPM4 obtained by voltage ramps spanning −100 to +100 mV and delivered from holding potentials of −60 and +60 mV are illustrated in Fig. 3B. They illustrate the typical characteristics of TRPM4 as reported previously (Launay et al., 2002; Hofmann et al., 2003; Nilius et al., 2003). The data sets obtained at different holding potentials demonstrate that the magnitude of inward currents carried by TRPM4 is strongly dependent on the holding potential from which the voltage ramps are delivered. The maximum current amplitude obtained when holding the cell membrane potential at negative values is consid-

---

**Fig. 3.** Voltage dependence of TRPM4 and facilitation by BTP2. Whole-cell currents were recorded in HEK-293 cells overexpressing TRPM4. Data are ± S.E.M. where applicable. A, TRPM4 currents were activated using intracellular solutions with [Ca²⁺], buffered to 1.3 µM and monitored by applying voltage ramps of 50-ms duration that ranged from −100 to +100 mV from a holding potential of either −60 or +60 mV (n = 6 each). Note the strong suppression of inward currents of TRPM4 at holding potential of −60 mV. B, representative I-V relationships for TRPM4 at the two holding potentials collected 6 s after whole-cell break-in. C, average inward peak current sizes measured with 1.8 µM internal calcium and at holding potentials indicated (n = 3–6). D, dose-response curves for maximal TRPM4 inward currents at −80 mV as a function of [Ca²⁺], and at different holding potentials as indicated in the graph. The values at the right of each data set represent the half-maximal Ca²⁺ concentration for TRPM4 activation. Note that these values are very similar, demonstrating that the [Ca²⁺], dependence of TRPM4 remains unaffected by the holding potential (n = 3–6). E, average inward currents carried by TRPM4 at −80 mV with [Ca²⁺], clamped at 500 nM (n = 5). Control cells produce very small TRPM4 inward currents, whereas cells pretreated for 2 to 3 min with 10 µM BTP2 produce large TRPM4 currents, even at this negative holding potential (n = 5). F, current-voltage relationship under experimental conditions as in E, obtained from a representative cell 170 s after whole-cell establishment.
erably smaller than that obtained at more depolarized holding potentials (Fig. 3A). The bar graph of Fig. 3C illustrates the voltage dependence of maximum inward currents obtained by perfusing cells with 1.8 μM free Ca\(^{2+}\).

A more comprehensive analysis of this voltage dependence is presented in Fig. 3D, in which we plot the maximum current amplitudes of TRPM4 currents (extracted from ramp currents at −80 mV) as a function of [Ca\(^{2+}\)]\(_i\), and measured in cells that were held at different holding potentials (−60, −30, and +60 mV). From this analysis, it is clear that the degree of TRPM4 activation is dependent on both [Ca\(^{2+}\)]\(_i\) and the membrane potential, with increasing Ca\(^{2+}\) and positive voltages synergizing to recruit larger maximal currents. The dose-response curves fitted to the various data sets of Fig. 3D reveal that the holding potential does not affect the responsiveness of TRPM4 to [Ca\(^{2+}\)]\(_i\), because the apparent EC\(_{50}\) for TRPM4 activation remains fairly constant at ~500 nM, regardless of the holding potential (Fig. 3D). From this, we infer that the primary effect of membrane potential on TRPM4 activity resides at the level of the channel’s open probability, which is consistent with our previous observations in single-channel recordings of TRPM4, in which negative membrane voltages strongly reduced their open probability (Launay et al., 2002).

**Effect of BTP2 on TRPM4 in HEK-293 Cells.** Based on the above observations, we reasoned that BTP2 could potentially increase the open probability of TRPM4 at negative membrane potentials. We therefore kept the holding potential of HEK-293 cells overexpressing TRPM4 at −80 mV and then tested BTP2 for possible augmentation of inward currents. Figure 3E illustrates the average inward currents carried by TRPM4 at −80 mV with [Ca\(^{2+}\)]\(_i\) clamped at 500 nM. Control cells indeed showed a significantly reduced TRPM4 current at this negative holding potential, and these were greatly enhanced when cells were pretreated with 10 μM BTP2 for several minutes. The current-voltage relationships illustrated in Fig. 3F were obtained from representative control and BTP2-treated cells at 170 s after whole-cell establishment, and they demonstrate the massive up-regulation of TRPM4 currents by BTP2. These results suggest that BTP2 can facilitate TRPM4 channels overexpressed in the heterologous expression system.

**Effect of BTP2 on I\(_{CAN}\) in Jurkat T Cells.** Fig. 4A demonstrates that I\(_{CAN}\) in Jurkat cells also exhibits strong voltage dependence. Cells kept at a holding potential of 0 mV and perfused with pipette solutions in which [Ca\(^{2+}\)]\(_o\) was buffered to 500 nM yielded large cation currents (Fig. 4A) with the typical current-voltage relationship of TRPM4 (Fig. 4B). Under the same experimental conditions, cells kept at a holding potential of −80 mV exhibited strongly reduced I\(_{CAN}\) current amplitudes (Fig. 4A), quite analogous to the observations made with TRPM4 in the heterologous expression system (Fig. 3A). Under these conditions, BTP2 did not enhance any currents when [Ca\(^{2+}\)]\(_o\) was buffered to resting levels of 100 nM or lower (data not shown). However, when intracellular solutions were buffered to a slightly elevated [Ca\(^{2+}\)]\(_i\), level of 500 nM, the preincubation of Jurkat cells with various concentrations of BTP2 resulted in a dose-dependent enhancement of Ca\(^{2+}\)-activated inward currents (Fig. 4C). The effect manifested itself in both an increase in maximal current amplitude and in the acceleration of the kinetics with which I\(_{CAN}\) developed. We analyzed the facilitation of I\(_{CAN}\) by constructing dose-response relationships for BTP2-mediated increases in inward currents as a function of BTP2 concentration 300 s after whole-cell recording (Fig. 4D). The apparent half-maximal effective concentration (EC\(_{50}\)) was 8 nM. Thus, the potency of BTP2 to enhance I\(_{CAN}\) is roughly 100-fold higher than that of inhibiting I\(_{CRAC}\) and close to its efficacy in inhibiting IL-2 production. We therefore propose that the primary action of BTP2 is based on its ability to shift the voltage dependence of TRPM4, so that open probability is increased at more negative membrane potentials. This effect enhances I\(_{CAN}\)-mediated cell membrane depolarization and thereby reduces the driving force for Ca\(^{2+}\) influx.

We sought to further corroborate the above hypothesis by...
assessing IL-2 production in Jurkat cells under experimental conditions that would negate the depolarizing action of $I_{\text{CAN}}$. This can be accomplished by extracellular solutions in which $\text{Na}^+$, the primary charge carrier of $I_{\text{CAN}}$, is replaced by an impermeant cation such as choline. This largely prevents TRPM4-mediated membrane depolarization and has been shown to enhance $\text{Ca}^{2+}$ influx (Launay et al., 2002). We analyzed the effect of BTP2 on PHA-stimulated IL-2 production in Jurkat cells cultured in the presence or absence of $\text{Na}^+$ in the extracellular medium. As illustrated in Fig. 4E, BTP2 potently inhibited IL-2 production in the presence of $\text{Na}^+$ with an IC$_{50}$ value of 0.25 nM. This value is lower than the IC$_{50}$ value reported previously of ~10 nM and may be a consequence of the Ringer’s-like extracellular solution used in the present study. When performing the IL-2 assay in choline-based $\text{Na}^+$-free media under otherwise identical conditions, the IC$_{50}$ value for BTP2-mediated inhibition of IL-2 production was reduced by approximately 100-fold (IC$_{50} =$ 14 nM). This result is entirely consistent with the notion that at low concentrations, BTP2 acts primarily via the facilitation of $I_{\text{CAN}}$. The specificity of the $\text{Na}^+$ removal experiment is demonstrated by the dose-response curves of econazole-mediated inhibition of IL-2 production under the same experimental conditions (Fig. 4F). Here, the removal of $\text{Na}^+$ did not alter the efficacy of econazole to suppress cytokine production.

**Discussion**

Our results establish a novel principle in regulating cytokine release from lymphocytes, a process that is intimately linked to elevations in $[\text{Ca}^{2+}]_i$. We demonstrate that the pyrazole compound BTP2, a potent inhibitor of IL-2 release in lymphocytes, effectively facilitates the activity of the $[\text{Ca}^{2+}]_i$-activated nonselective cation channel TRPM4 both in a heterologous expression system and in Jurkat cells, which express the protein natively. The efficacy of facilitating $I_{\text{CAN}}$ and the ability to suppress cytokine production occur in the low nanomolar concentration range within a few minutes of BTP2 exposure, suggesting that the primary mechanism of action of BTP2 is due to its effect on TRPM4. At higher concentrations, the compound can also inhibit $I_{\text{CRAC}}$. Even at these higher concentrations, the specificity of BTP2 for $I_{\text{CRAC}}$ seems remarkable compared with the effects on a range of other ion channels found in lymphocytes. Thus, of all compounds known presently to inhibit $I_{\text{CRAC}}$, BTP2 represents the most potent and most selective $I_{\text{CRAC}}$ inhibitor, even though its primary mechanism of action seems linked to TRPM4.

BTP2 appears to be a very potent inhibitor of T-cell activation in the low nanomolar range (Djuric et al., 2000; Trevillyan et al., 2001; Chen et al., 2002; Ishikawa et al., 2003; see Figs. 1 and 4), and it inhibits $[\text{Ca}^{2+}]_i$ signals within a few minutes (Fig. 1G). Any mechanism that accounts for this effect should match the potency and kinetic aspects of BTP2 action. So far, three mechanisms of BTP2 have been proposed to account for its inhibitory effects on $\text{Ca}^{2+}$ influx and cytokine production: the inhibition of the store-operated current $I_{\text{CRAC}}$ (Zitt et al., 2004; He et al., 2005), the inhibition of the TRPC channels TRPC3 and TRPC5b (He et al., 2005), and the facilitation of TRPM4 (the present study).

All three studies agree that store-operated $\text{Ca}^{2+}$ influx is compromised by BTP2; however, discrepancies exist in terms of potency and kinetics of block. Zitt et al. (2004) attribute BTP2’s potent suppression of $\text{Ca}^{2+}$ influx in lymphocytes in the low nanomolar range to a slow block of $I_{\text{CRAC}}$ that develops over hours. He et al. (2005) did not measure $I_{\text{CRAC}}$ directly but found that thapsigargin and receptor-mediated $\text{Ca}^{2+}$ signals were inhibited within approximately 10 min, but the potency was at least 1 order of magnitude higher (IC$_{50} =$ 0.1–0.3 µM). It should be noted that the IC$_{50}$ values reported by Gill and colleagues (He et al., 2005) are not directly comparable with the values provided by Zitt et al. (2004) or our own study, because they represent only indirect measures of channel activity as determined from changes in $[\text{Ca}^{2+}]_i$, and therefore probably overestimate the true potency at the channel level. Our study finds that $I_{\text{CRAC}}$ in RBL and Jurkat T cells can indeed be inhibited relatively quickly within a few minutes, and potencies range from 0.5 to 4 µM as derived from direct current inhibition profiles. Whereas the study of Zitt et al. (2004) is compatible with the potency range of BTP2 on inhibition of cytokine production, the slow kinetics of $I_{\text{CRAC}}$ inhibition reported by Zitt et al. (2004) is at odds with the relatively fast inhibition of $\text{Ca}^{2+}$ influx (Fig. 1G). Conversely, the studies by He et al. (2005) and our own data are compatible with the kinetics of inhibition of store-operated currents, but neither study found a low nanomolar potency that would be required to explain the efficacy of BTP2 in terms of $I_{\text{CRAC}}$ inhibition alone. Likewise, the efficacy of BTP2 in blocking other channels such as heterologously expressed TRPC3 and TRPC5, which He et al. (2005) estimate to be ~0.3 µM, does not approach the low BTP2 concentrations that suffice to mediate the inhibition of cytokine release in native T cells. These channels also would not seem to be responsible for BTP-mediated inhibition of cytokine release from lymphocytes, because the only $\text{Ca}^{2+}$-permeable current elicited by either antigen or thapsigargin stimulation seems to be $I_{\text{CRAC}}$, and no ion channels that fit the profile of TRPC3 or TRPC5 have so far been reported in the literature. From these considerations and based on the data present in this study, it seems that the only mechanism which fits the criteria for BTP2 effects in T cells in terms of potency and kinetics is provided by the facilitation of TRPM4. Not only are the potency and kinetic properties adequate, but these channels have been identified in T cells as important factors in determining the amount of $\text{Ca}^{2+}$ influx (Launay et al., 2004). At higher concentrations, $I_{\text{CRAC}}$ inhibition may contribute to this inhibition. Likewise, at these higher concentrations and in cell types that express TRPC3/TRPC5, the BTP2 effects may also involve inhibition of TRPC channels.

**Acknowledgments**

We thank Mahealani K. Monteilh-Zoller and Carolyn E. Oki for expert technical assistance.

**References**

Bodding M (2001) Reduced store-operated $\text{Ca}^{2+}$ currents in rat basophilic leukaemia cells cultured under serum-free conditions. *Cell Calcium* 30:141–150.


